Atricure vs Bioventus
Atricure and Bioventus are similar in size: $535m and $568m of revenue in their latest fiscal years. Atricure grew faster (14.9% against -0.9%). Bioventus kept more of each dollar of sales as profit: a net margin of 4.0% against -2.1%.
| Latest fiscal year | AtricureATRC, 2025 | BioventusBVS, 2025 |
|---|---|---|
| Revenue | $535m | $568m |
| Revenue growth | 14.9% | -0.9% |
| Net income | −$11.4m | $22.7m |
| Operating margin | — | 9.5% |
| Net margin | -2.1% | 4.0% |
| Return on equity | -2.4% | 13.7% |
| Free cash flow | $48.3m | $72.1m |
| Cash | $167m | $51.2m |
| Total debt | $61.9m | $294m |
| Debt to equity | — | 159.7% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 1,350 | 930 |
| Market value | $3.07bn | $795m |
| Price vs our value range | — | Within our value range |
| Moat score | 39 (Weak) | 43 (Weak) |
| Insider trades, 12 months | 0 buys, 17 sales | 0 buys, 3 sales |